Supplementary Information

Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: a retrospective analysis

Yuxin Xie, MD, PhD 1,2﹡, Xingxing Lv, MD 1,2﹡, Chuanxu Luo, MD, PhD 1,2,

Kejia Hu, MD 1,2, Qiheng Gou, MD, PhD 3, Keqi Xie, MD 4, Hong Zheng, MD, PhD, 1,2

1 Cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

2 Laboratory of Molecular Diagnosis of Cancer, State Key Laboratory of Biotherapy, National Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

3State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China

4Departments of Anesthesiology, Mianyang Central Hospital, Mianyang, Sichuan, 621000, China

Correspondence to: Hong Zheng, M.D., Ph.D.

Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, Sichuan University West China Hospital, 37 Guoxuexiang, Wuhou District, Chengdu 610041, China

E-mail:

﹡ These authors contributed to the work equally

Supplementary Table 1. Patient characteristics which had no difference in the surgery group and non-surgery group.

Characteristics / All / Surgery / Non-surgery
N / % / N / % / N / % / p
223 / 177 / (79.4%) / 46 / (20.6%)
Age, years
Median (range) 49 / (22-87) / 50 / (27-87) / 46 / (22-69) / 0.320
≤50 / 125 / (56.1%) / 96 / (54.2%) / 29 / (63.0%)
50 / 98 / (43.9%) / 81 / (45.8%) / 17 / (37.0%)
T-stage / 0.106
I / 15 / (6.7%) / 13 / (7.3%) / 2 / (4.3%)
II / 73 / (32.7%) / 64 / (36.2%) / 9 / (19.6%)
III / 23 / (10.3%) / 17 / (9.6%) / 6 / (13.0%)
IV / 106 / (47.6%) / 78 / (44.1%) / 28 / (60.9%)
Unknown / 6 / (2.7%) / 5 / (2.8%) / 1 / (2.2%)
N-stage / 0.177
0 / 24 / (10.8%) / 23 / (13.0%) / 1 / (2.2%)
I / 45 / (20.2%) / 37 / (20.9%) / 8 / (17.4%)
II / 56 / (25.0%) / 43 / (24.3%) / 13 / (28.3%)
III / 94 / (42.2%) / 72 / (40.7%) / 22 / (47.8%)
Unknown / 4 / (1.8%) / 2 / (1.1%) / 2 / (4.3%)
Histologic grade / 0.471
I / 4 / (1.8%) / 4 / (2.3%) / 0 / -
II / 50 / (22.4%) / 45 / (25.4%) / 5 / (10.9%)
III / 63 / (28.3%) / 60 / (33.9%) / 3 / (6.5%)
Unknown / 106 / (47.5%) / 68 / (38.4%) / 38 / (82.6%)
Molecular subtype / 0.597
Luminal A / 13 / (5.8%) / 9 / (5.9%) / 4 / (8.7%)
Luminal B1 / 86 / (38.6%) / 72 / (40.7%) / 14 / (30.4%)
Luminal B2 / 34 / (15.2%) / 27 / (15.3%) / 7 / (15.2%)
HER2-type / 22 / (9.9%) / 17 / (9.6%) / 5 / (10.9%)
Triple-negative / 37 / (16.6%) / 27 / (15.4%) / 10 / (21.8%)
Unknown / 31 / (13.9%) / 25 / (14.1%) / 6 / (13.0%)
HR / 0.253
Negative / 62 / (27.8%) / 47 / (26.6%) / 15 / (32.6%)
Positive / 152 / (68.2%) / 126 / (71.1%) / 26 / (56.5%)
Unknown / 9 / (4.0%) / 4 / (2.3%) / 5 / (10.9%)
Metastatic sites
Bone / 0.74
Yes / 131 / (58.7%) / 105 / (59.3%) / 26 / (56.5%)
No / 92 / (41.3%) / 72 / (40.7%) / 20 / (43.5%)
Brain / 0.851
Yes / 26 / (11.7%) / 21 / (11.9%) / 5 / (10.9%)
No / 197 / (88.3%) / 156 / (88.1%) / 41 / (89.1%)
Liver / 0.082
Yes / 96 / (43.0%) / 71 / (40.2%) / 25 / (54.3%)
No / 127 / (57.0%) / 106 / (59.8%) / 21 / (45.7%)
No. metastasis sites / 0.192
1 / 111 / (49.8%) / 93 / (52.5%) / 18 / (39.1%)
2 / 57 / (25.6%) / 41 / (23.2%) / 16 / (34.8%)
≥3 / 55 / (24.7%) / 43 / (24.3%) / 12 / (26.1%)
Chemotherapy / 0.921
No / 5 / (2.2%) / 4 / (2.2%) / 1 / (2.2%)
Yes / 206 / (92.4%) / 161 / (91.0%) / 45 / (9.8%)
Unknown / 12 / (5.4%) / 12 / (6.8%) / 0

HR, hormone receptor; HER-2, human epidermal growth factor receptor-2.

Supplementary Information

Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: a retrospective analysis

Yuxin Xie, MD, PhD 1,2﹡, Xingxing Lv, MD 1,2﹡, Chuanxu Luo, MD, PhD 1,2,

Kejia Hu, MD 1,2, Qiheng Gou, MD, PhD 3, Keqi Xie, MD 4, Hong Zheng, MD, PhD, 1,2

1 Cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

2 Laboratory of Molecular Diagnosis of Cancer, State Key Laboratory of Biotherapy, National Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

3State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China

4Departments of Anesthesiology, Mianyang Central Hospital, Mianyang, Sichuan, 621000, China

Correspondence to: Hong Zheng, M.D., Ph.D.

Departments of Head and Neck and Mammary Gland Oncology, and Medical Oncology, Cancer Center; State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, Sichuan University West China Hospital, 37 Guoxuexiang, Wuhou District, Chengdu 610041, China

E-mail:

﹡ These authors contributed to the work equally

Supplementary Table 2. Patient characteristics in modified radical mastectomy and radical mastectomy groups.

Characteristics / All / Modified radical mastectomy / Radical
mastectomy
N / % / N / % / N / % / p
172 / 115 / 66.90% / 57 / 33.10%
Age, years / 0.255
≤50 / 94 / 54.65% / 59 / 51.30% / 35 / 61.40%
>50 / 78 / 45.35% / 56 / 48.70% / 22 / 38.60%
Residence / 0.599
Rural / 52 / 30.23% / 33 / 28.70% / 19 / 33.33%
Urban / 119 / 69.19% / 81 / 70.43% / 38 / 66.67%
Unknown / 1 / 0.58% / 1 / 0.87% / 0 / 0.00%
Menopause / 0.106
No / 90 / 52.33% / 55 / 47.83% / 35 / 61.40%
Yes / 82 / 47.67% / 60 / 52.17% / 22 / 38.60%
Pathology / 0.623
IDC / 152 / 88.37% / 100 / 86.96% / 52 / 91.23%
ILC / 14 / 8.14% / 10 / 8.70% / 4 / 7.02%
Others / 6 / 3.49% / 5 / 4.35% / 1 / 1.75%
T-stage / 0.295
I / 13 / 7.56% / 11 / 9.57% / 2 / 3.51%
II / 60 / 34.88% / 40 / 34.78% / 20 / 35.09%
III / 17 / 9.88% / 13 / 11.30% / 4 / 7.02%
IV / 77 / 44.77% / 47 / 40.87% / 30 / 52.63%
Unknown / 5 / 2.91% / 4 / 3.48% / 1 / 1.75%
N-stage / 0.005
0 / 22 / 12.79% / 19 / 16.52% / 3 / 5.26%
I / 37 / 21.51% / 28 / 24.35% / 9 / 15.79%
II / 41 / 23.84% / 30 / 26.09% / 11 / 19.30%
III / 71 / 41.28% / 37 / 32.17% / 34 / 59.65%
Unknown / 1 / 0.58% / 1 / 0.87% / 0 / 0.00%
HR / 0.102
Negative / 47 / 27.33% / 36 / 31.30% / 11 / 19.30%
Positive / 121 / 70.35% / 75 / 65.22% / 46 / 80.70%
Unknown / 4 / 2.33% / 4 / 3.48% / 0 / 0.00%
HER2 / 1.00
Negative / 111 / 64.53% / 71 / 61.74% / 40 / 70.18%
Positive / 43 / 25.00% / 28 / 24.35% / 15 / 26.32%
Unknown / 18 / 10.47% / 16 / 13.91% / 2 / 3.51%
Metastatic sites
Bone / 0.417
Yes / 101 / 58.72% / 65 / 56.52% / 36 / 63.16%
No / 71 / 41.28% / 50 / 43.48% / 21 / 36.84%
Brain / 0.462
Yes / 20 / 11.63% / 15 / 13.04% / 5 / 8.77%
No / 152 / 88.37% / 100 / 86.96% / 52 / 91.23%
Liver / 0.189
Yes / 69 / 40.12% / 42 / 36.52% / 27 / 47.37%
No / 103 / 59.88% / 73 / 63.48% / 30 / 52.63%
Lung / 0.073
Yes / 49 / 28.49% / 38 / 33.04% / 11 / 19.30%
No / 123 / 71.51% / 77 / 66.96% / 46 / 80.70%
No. metastasis sites / 0.193
1 / 148 / 86.05% / 100 / 86.96% / 48 / 84.21%
2 / 20 / 11.63% / 14 / 12.17% / 6 / 10.53%
≥3 / 4 / 2.33% / 1 / 0.87% / 3 / 5.26%
Chemotherapy / 1.00
No / 4 / 2.33% / 3 / 2.61% / 1 / 1.75%
Yes / 157 / 91.28% / 104 / 90.43% / 53 / 92.98%
Unknown / 11 / 6.40% / 8 / 6.96% / 3 / 5.26%
Hormonal therapy / 0.326
No / 77 / 44.8% / 55 / 47.83% / 22 / 38.60%
Yes / 93 / 54.1% / 59 / 51.30% / 34 / 59.65%
Unknown / 2 / 1.1% / 1 / 0.87% / 1 / 1.75%
Radiotherapy / 0.134
No / 97 / 56.4% / 70 / 60.87% / 27 / 47.37%
Yes / 69 / 40.1% / 42 / 36.52% / 27 / 47.37%
Unknown / 6 / 3.5% / 3 / 2.61% / 3 / 5.26%

IDC: invasive ductal carcinoma, ILC: Invasive lobular carcinoma; HR, hormone receptor; HER-2, human epidermal growth factor receptor-2.

6